AIM: To study the institutional experience over 8 years with 200 continuous-flow (CF) - left ventricular assist devices (LVAD). METHODS: We evaluated our institution's LVAD database and analyzed all patients who received a CF LVAD as a bridge to transplant (BTT) or destination therapy from March 2006 until June 2014. We identified 200 patients, of which 179 were implanted with a HeartMate II device (Thoratec Corp., Pleasanton, CA) and 21 received a Heartware HVAD (HeartWare Inc., Framingham, MA). RESULTS: The mean age of our LVAD recipients was 59.3 years (range 17-81), 76% (152/200) were males, and 49% were implanted for the indication of BTT. The survival rate for our LVAD patients at 30 d, 6 mo, 12 mo, 2 years, 3 years, and 4 years was 94%, 86%, 78%, 71%, 62% and 45% respectively. The mean duration of LVAD support was 581 d (range 2-2595 d). Gastrointestinal bleeding (was the most common adverse event (43/200, 21%), followed by right ventricular failure (38/200, 19%), stroke (31/200, 15%), re exploration for bleeding (31/200, 15%), ventilator dependent respiratory failure (19/200, 9%) and pneumonia (15/200, 7%). Our driveline infection rate was 7%. Pump thrombosis occurred in 6% of patients. Device exchanged was needed in 6% of patients. On multivariate analysis, preoperative liver dysfunction, ventilator dependent respiratory failure, tracheostomy and right ventricular failure requiring right ventricular assist device support were significant predictors of post LVAD survival. CONCLUSION: Short and long term survival for patients on LVAD support are excellent, although outcomes still remain inferior compared to heart transplantation. The incidence of driveline infections, pump thrombosis and pump exchange have declined significantly in recent years.
AIM: To study the institutional experience over 8 years with 200 continuous-flow (CF) - left ventricular assist devices (LVAD). METHODS: We evaluated our institution's LVAD database and analyzed all patients who received a CF LVAD as a bridge to transplant (BTT) or destination therapy from March 2006 until June 2014. We identified 200 patients, of which 179 were implanted with a HeartMate II device (Thoratec Corp., Pleasanton, CA) and 21 received a Heartware HVAD (HeartWare Inc., Framingham, MA). RESULTS: The mean age of our LVAD recipients was 59.3 years (range 17-81), 76% (152/200) were males, and 49% were implanted for the indication of BTT. The survival rate for our LVAD patients at 30 d, 6 mo, 12 mo, 2 years, 3 years, and 4 years was 94%, 86%, 78%, 71%, 62% and 45% respectively. The mean duration of LVAD support was 581 d (range 2-2595 d). Gastrointestinal bleeding (was the most common adverse event (43/200, 21%), followed by right ventricular failure (38/200, 19%), stroke (31/200, 15%), re exploration for bleeding (31/200, 15%), ventilator dependent respiratory failure (19/200, 9%) and pneumonia (15/200, 7%). Our driveline infection rate was 7%. Pump thrombosis occurred in 6% of patients. Device exchanged was needed in 6% of patients. On multivariate analysis, preoperative liver dysfunction, ventilator dependent respiratory failure, tracheostomy and right ventricular failure requiring right ventricular assist device support were significant predictors of post LVAD survival. CONCLUSION: Short and long term survival for patients on LVAD support are excellent, although outcomes still remain inferior compared to heart transplantation. The incidence of driveline infections, pump thrombosis and pump exchange have declined significantly in recent years.
Entities:
Keywords:
Continuous-flow; Heart failure; Left ventricular assist device; Outcomes
Authors: M R Moon; A F Bolger; A DeAnda; M Komeda; G T Daughters; S D Nikolic; D C Miller; N B Ingels Journal: Circulation Date: 1997-03-04 Impact factor: 29.690
Authors: D L Morales; K A Catanese; D N Helman; M R Williams; A Weinberg; D J Goldstein; E A Rose; M C Oz Journal: J Thorac Cardiovasc Surg Date: 2000-02 Impact factor: 5.209
Authors: Hiroyuki Tsukui; Adib Abla; Jeffrey J Teuteberg; Dennis M McNamara; Michael A Mathier; Linda M Cadaret; Robert L Kormos Journal: J Thorac Cardiovasc Surg Date: 2007-06-04 Impact factor: 5.209
Authors: Jamil Borgi; Athanasios Tsiouris; Arielle Hodari; Chad M Cogan; Gaetano Paone; Jeffrey A Morgan Journal: Ann Thorac Surg Date: 2012-10-25 Impact factor: 4.330
Authors: Anton Sabashnikov; Prashant N Mohite; Bartlomiej Zych; Diana García; Aron-Frederik Popov; Alexander Weymann; Nikhil P Patil; Rachel Hards; Massimo Capoccia; Thorsten Wahlers; Fabio De Robertis; Toufan Bahrami; Mohamed Amrani; Nicholas R Banner; André R Simon Journal: ASAIO J Date: 2014 Mar-Apr Impact factor: 2.872
Authors: Justin T Parizo; Jeremy D Goldhaber-Fiebert; Joshua A Salomon; Kiran K Khush; John A Spertus; Paul A Heidenreich; Alexander T Sandhu Journal: JAMA Cardiol Date: 2021-08-01 Impact factor: 30.154